Actively Recruiting
Liposomal Bupivacaine/Bupivacaine in Rectus Sheath Blocks Versus Ropivacaine in Rectus Sheath Blocks And Catheters
Led by Hartford Hospital · Updated on 2025-09-03
14
Participants Needed
1
Research Sites
167 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this pilot study is to compare single shot rectus sheath blocks of liposomal bupivacaine/bupivacaine mixture to bilateral rectus sheath catheters infused with ropivacaine (standard of care at our facility) in patients undergoing vascular surgery with an open mid-abdominal laparotomy incision. This study will assess the safety and feasibility of this approach compared to standard of care. Participants will receive either a single dose of liposomal bupivacaine/bupivacaine mixture intraoperatively at the end of surgery through bilateral rectus sheath blocks (LB/B group) or the standard of care ropivacaine intraoperatively at the end of surgery through bilateral rectus sheath blocks with the insertion of bilateral RS catheter for continuous ropivacaine infusion plus repeated daily boluses (Catheter group; standard care). They will be assessed for differences in the rate of postoperative complications, resources consumed with each intervention, as well as postoperative pain scores, opioid consumption, hospital and PACU length of stay, patient's satisfaction, and quality of recovery, and hospital length of stay.
CONDITIONS
Official Title
Liposomal Bupivacaine/Bupivacaine in Rectus Sheath Blocks Versus Ropivacaine in Rectus Sheath Blocks And Catheters
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18-80 years
- Scheduled for elective vascular surgery with an open mid-abdominal laparotomy incision, including abdominal aortic aneurysm repair, mesenteric artery bypass, or aortobifemoral bypass
- Able to speak and read English
- American Society of Anesthesiology physical status score I-IV
- Patients admitted to the hospital and found to require the above surgeries with surgery scheduled at least three days after admission
You will not qualify if you...
- Emergency vascular surgery or surgery due to symptomatic vascular conditions like severe abdominal pain or ruptured aneurysm
- Contraindications to rectus sheath block such as anatomical abnormalities, prior surgery preventing blocks, or infection at injection site
- Allergy to local anesthetics
- Weight less than 40 kg due to risk of anesthetic toxicity
- Use of long-acting opioids or continuous opioid use greater than 50 MME per day for at least 30 days within 90 days before surgery
- Chronic pain syndrome with recent consultation or distant metastatic cancer confirmed by CT scan
- Current or recent substance abuse including illicit drugs (excluding marijuana) or excessive alcohol consumption
- Refusal or inability to sign study consent
- Inability to receive postoperative ropivacaine boluses due to catheter issues
- Planned additional abdominal wall surgery alongside vascular surgery affecting study outcomes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hartford Hospital
Hartford, Connecticut, United States, 06102
Actively Recruiting
Research Team
A
Aseel Walker, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here